Heidelberg Pharma to Present New HDP-101 Data at IMS Annual Meeting

Heidelberg Pharma AG is set to present new clinical data on its lead Antibody Drug Conjugate (ADC) HDP-101 at the International Myeloma Society Annual Meeting in Toronto. This event, held from September 17 to 20, 2025, will showcase findings from their Phase I/IIa clinical study targeting relapsed or refractory multiple myeloma.

HDP-101 is noted for its Anti-BCMA Amanitin-based ADC approach in treating this form of bone marrow cancer. The ongoing trial aims to determine optimal dosing before advancing into a second phase. Initial results from the first seven patient cohorts suggest promising tolerance and significant anti-tumor activity. A notable outcome includes one patient showing no detectable tumor cells after treatment.

Professor Jonathan L. Kaufman will deliver detailed insights during a presentation session on September 20.